Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2012

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Imatinib mesylate

Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6

DRUG

Paclitaxel

Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6

Trial Locations (3)

87102

University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque

87106

University of New Mexico Cancer Center, Albuquerque

98109-1024

Univ. of Washington Fred Hutchinson Cancer Research Center (UW-FHCRC), Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Fred Hutchinson Cancer Center

OTHER

collaborator

Novartis

INDUSTRY

lead

New Mexico Cancer Research Alliance

OTHER